Arch Therapeutics's total inventories for the quarter that ended in Jun. 2024 was $1.32 Mil. Arch Therapeutics's average total inventories from the quarter that ended in Mar. 2024 to the quarter that ended in Jun. 2024 was $1.33 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Arch Therapeutics's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was $-2.99.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Arch Therapeutics's Days Inventory for the
three
months ended in Jun. 2024 was 5,757.44.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Arch Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2024 was 0.02.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Arch Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 42.74.
Arch Therapeutics (OTCPK:ARTHQ) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Arch Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Arch Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Arch Therapeutics Total Inventories Related Terms
Arch Therapeutics Total Inventories Historical Data
* Premium members only.
The historical data trend for Arch Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Arch Therapeutics (ARTHQ) has a Total Inventories of $1.32 Mil as of Jun. 2024. The total amount of inventory as recorded on a company's balance sheet. View historical data for Arch Therapeutics and its competitors.
Is Arch Therapeutics' Total Inventories too high?
Arch Therapeutics' current Total Inventories is $1.32 Mil. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Total Inventories compare to GRTSQ and MTEM?
Arch Therapeutics' Total Inventories of $1.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Arch Therapeutics and its competitors. Arch Therapeutics's current Total Inventories is $1.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Total Inventories of $1.32 Mil. The current Total Inventories is $1.32 Mil. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Total Inventories is $1.32 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score
Get the complete analysis for ARTHQ
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTHQ has been successfully added to your 
